Stefano Arcangeli
University of Milan
Acute toxicityCancerInternal medicineRadiologyUrologySurgeryOncologyDose fractionationRandomized controlled trialStage (cooking)Medical physicsProstateAndrogen deprivation therapyProstate cancerRadiosurgeryToxicityNuclear medicinePhases of clinical researchRadiation therapyMedicine
125Publications
24H-index
2,147Citations
Publications 124
Newest
#2Angela Sardaro (University of Bari)H-Index: 8
Last. Artor Niccoli AsabellaH-Index: 12
view all 0 authors...
BACKGROUND AND PURPOSE The potential for unintended and adverse radiation exposure in radiotherapy is real and should be studied because radiotherapy is a highly complex, multistep process which requires input from numerous individuals from different areas and steps of the radiotherapy workflow. The 'Incident' (I) is a consequence of which are not negligible from the point of view of protection or safety. A 'near miss' (NM) is defined as an event which is highly likely to happen but did not occu...
Source
#1Francesca De Felice (Sapienza University of Rome)H-Index: 21
#2Liliana Belgioia (UniGe: University of Genoa)H-Index: 11
Last. Stefano Arcangeli (University of Milan)H-Index: 24
view all 14 authors...
Abstract Purpose To evaluate efficacy and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy and identify differences in clinical outcomes and severe toxicity rate. Methods PICOS/PRISMA methods were used to identify studies on PubMed, EMBASE and Cochrane Library, 2005–2019. Results Six randomized clinical trials (554 patients) were identified. Weekly cisplatin was not associated with significant overall survival (HR 1.13, 95 % CI 0.84–1.51) and progres...
Source
#1E. MazzeoH-Index: 8
#2Luca TriggianiH-Index: 15
Last. Stefano Maria MagriniH-Index: 25
view all 22 authors...
BACKGROUND AND PURPOSE Two previous "Patterns Of Practice" surveys (POP I and POP II), including more than 4000 patients affected by prostate cancer treated with radical external beam radiotherapy (EBRT) between 1980 and 2003, established a "benchmark" Italian data source for prostate cancer radiotherapy. This report (POP III) updates the previous studies. METHODS Data on clinical management and outcome of 2525 prostate cancer patients treated by EBRT from 2004 to 2011 were collected and compare...
Source
#1Marta Bottero (University of Rome Tor Vergata)H-Index: 5
#2V. BorzilloH-Index: 5
Last. Rolando Maria D'Angelillo (University of Rome Tor Vergata)H-Index: 20
view all 12 authors...
Source
#1Anna MerlottiH-Index: 11
#2Alessio BruniH-Index: 15
Last. Stefano Arcangeli (University of Milan)H-Index: 24
view all 13 authors...
INTRODUCTION Almost 30% of non-small cell lung cancer (NSCLC) patients have locally advanced-stage disease. In this setting, definitive radiotherapy concurrent to chemotherapy plus adjuvant immunotherapy (cCRT + IO) is the standard of care, although only 40% of these patients are eligible for this approach. AIMS A comparison between cCRT and hypofractionated radiotherapy regimens (hypo-fx RT) with the addition of sequential chemotherapy (sCHT) could be useful for future combinations with immunot...
Source
#1Barbara Alicja Jereczek-Fossa (IEO: European Institute of Oncology)H-Index: 36
#2Mauro PalazziH-Index: 11
Last. Carlo Pietro SoattiH-Index: 4
view all 39 authors...
Lombardy has represented the Italian and European epicenter of the coronavirus disease 2019 (COVID-19) pandemic. Although most clinical efforts within hospitals were diverted towards the care of virally infected patients, therapies for patients with cancer, including radiotherapy (RT), have continued. During both the first and second pandemic waves, several national and regional organizations provided Italian and Lombardian RT departments with detailed guidelines aimed at ensuring safe treatment...
Source
#2Giulia MarvasoH-Index: 14
Last. Piet OstH-Index: 41
view all 36 authors...
Abstract Background and purpose Between 30% and 47% of patients treated with definitive radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up. Re-irradiation with stereotactic body RT (SBRT) is emerging as a feasible and safe therapeutic option. However, no consensus or guidelines exist on this topic. The purpose of this ESTRO ACROP project is to investigate expert opinion on salvage SBRT for intraprostatic relapse after RT. Materials and Methods A 40-it...
Source
#1Samantha Dicuonzo (IEO: European Institute of Oncology)H-Index: 7
#2Sara PedrettiH-Index: 7
Last. Rolando Maria D'Angelillo (University of Rome Tor Vergata)H-Index: 20
view all 14 authors...
Background:Treatment for locally advanced differentiated thyroid cancer is surgery followed by radioiodine while the role of adjuvant external beam radiotherapy (EBRT) is debated.Methods:The panel ...
Source
#1Fernando MunozH-Index: 11
#2Francesco FioricaH-Index: 16
Last. Mariangela Massaccesi (CUA: The Catholic University of America)H-Index: 16
view all 15 authors...
Abstract Aims The best therapeutic approach for local relapses of previously irradiated prostate cancer (PC) is still not defined. Re-irradiation (Re-I) could offer a chance of cure for highly selected patients, although high quality evidences are lacking. The aim of our study is to provide a literature review on efficacy and safety of Re-I. Methods Only studies where Re-I field overlaps with previous radiotherapy were considered. To determine 2 and 4 years overall mortality (OM), 2 and 4 years ...
Source
#1Sergio FersinoH-Index: 14
#2Simona BorghesiH-Index: 10
Last. Filippo Alongi (University of Brescia)H-Index: 15
view all 7 authors...
Aim To investigate the actual attitude of Radiation Oncologists in the prescription of hormonal therapy in prostate cancer (PC) with or without Radiation Therapy (RT). Materials and methods In 2019, a survey named Prescription of Radiation Oncologists ACtual Attitude including 18 items was sent to all Italian Radiation Oncologists of the Italian Association of Radiotherapy and Clinical Oncology. The first 4 items were about the Radiation Oncology Centers characteristics and years of practice of ...
1 CitationsSource